Myocardial Infarction News and Research

RSS

Elevated levels of cardiac troponins T or I after angioplasty linked to long-term all-cause mortality

New research shows that elevated levels of cardiac troponin T (cTnT) or I (cTnI) in patients who had angioplasty indicate a higher risk of all-cause mortality and long-term adverse events such as heart attack.

13 May 2011

FDA approves expanded access to RX Acculink stent for clogged neck artery treatment

The U.S. Food and Drug Administration today approved an expanded indication that will allow a new group of patients at risk of stroke due to clogged neck arteries to be treated with the RX Acculink carotid stent.

7 May 2011

Researchers establish new method to patch damaged heart with tissue-engineering platform

Researchers at Columbia Engineering have established a new method to patch a damaged heart using a tissue-engineering platform that enables heart tissue to repair itself.

7 May 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

Heart attacks in the morning are more serious

People who have a heart attack are likely to be more seriously affected if the attack happens in the morning, reveals research published ahead of print in Heart journal.

28 Apr 2011

Study finds increase in implementation of evidence-based therapies for myocardial infarction

In an analysis of data from a coronary care registry in Sweden, between 1996-2007 there was an increase in the prevalence of use of evidence-based invasive procedures and pharmacological therapies for treatment of a certain type of heart attack, and a decrease in the rate of death at 30 days and one year after a heart attack for these patients, according to a study in the April 27 issue of JAMA.

28 Apr 2011

Interventionalist-transfer strategy can improve heart attack patients' outcomes

In a large, traffic-congested city in China, severe heart attack patients received treatment faster and had better long-term results when interventional physicians were taken to them, according to a study in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

27 Apr 2011

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology.

25 Apr 2011

VDF seeks nominations for PAD and venous disease research awards

The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.

25 Apr 2011

Noninvasive Masimo carboxyhemoglobin can effectively screen ED patients for CO poisoning

Masimo announced today that a new study published in this month's issue of the peer-reviewed journal, Annals of Emergency Medicine, demonstrates that noninvasive Masimo carboxyhemoglobin measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis.

25 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

NeuroVive Pharmaceutical and Hospices Civils de Lyon today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction.

19 Apr 2011

Single antibody injection limits tissue and organ destruction after ischaemic events

Medical researchers today held out promise that a simple injection is being developed to limit the devastating consequences of heart attacks and strokes.

19 Apr 2011

New biomarker-based test more effective for early acute kidney injury detection

A new biomarker-based diagnostic test is more effective than the current best practice for early detection of adverse outcomes after acute kidney injury, which can be fatal for an estimated 50 percent of the critically ill patients who get the condition.

19 Apr 2011

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention.

16 Apr 2011

Pharmacological manipulation of DKK1, DKK2 can treat various vascular diseases

Angiogenesis, the development of new blood vessels, is required during embryonic development and wound healing, as well as during disease processes such as tumor growth. The signals that direct angiogensis are incompletely understood, but could represent novel targets for the development of therapies that promote or inhibit this process.

12 Apr 2011

BioParadox's VitaKine PCT can serve as promising therapy for heart attack patients

BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.

8 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

Milliman Care Guidelines honors Sound Physicians with prestigious award

Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and efficiency of inpatient healthcare delivery, today received the Doyle Award for Innovation and Leadership in Healthcare.

6 Apr 2011

Myocardial Infarction News and Research

Elevated levels of cardiac troponins T or I after angioplasty linked to long-term all-cause mortality

FDA approves expanded access to RX Acculink stent for clogged neck artery treatment

Researchers establish new method to patch damaged heart with tissue-engineering platform

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Heart attacks in the morning are more serious

Study finds increase in implementation of evidence-based therapies for myocardial infarction

Interventionalist-transfer strategy can improve heart attack patients' outcomes

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

VDF seeks nominations for PAD and venous disease research awards

Noninvasive Masimo carboxyhemoglobin can effectively screen ED patients for CO poisoning

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

Single antibody injection limits tissue and organ destruction after ischaemic events

New biomarker-based test more effective for early acute kidney injury detection

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

Pharmacological manipulation of DKK1, DKK2 can treat various vascular diseases

BioParadox's VitaKine PCT can serve as promising therapy for heart attack patients

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Milliman Care Guidelines honors Sound Physicians with prestigious award

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News